How Melanoma Is Treated at Each Stage

Melanoma is the “small spot, big deal” of skin cancers. The good news: treatment has come a long way, and a lot of
melanomas are cured with surgery aloneespecially when caught early. The tricky part is that melanoma treatment isn’t
one-size-fits-all. It’s stage-based, risk-based, and sometimes “biology-based” (meaning your tumor’s genetic quirks can
change the game plan).

This guide walks through how melanoma is typically treated at each stagefrom stage 0 (still on the skin’s surface) to
stage IV (spread to distant organs). Along the way, you’ll see why terms like wide local excision,
sentinel lymph node biopsy, adjuvant therapy, and immunotherapy keep showing upbecause in melanoma,
they’re basically the main characters.

Quick note: This is educational information, not personal medical advice. Melanoma care is highly individualized,
so your dermatologist/oncologist is the real boss battle.

First, a Fast (Useful) Staging Refresher

Melanoma staging describes how deep the tumor goes and whether it has spread. Doctors use biopsy results and sometimes
imaging to stage it. Staging also depends on details like tumor thickness (often called Breslow depth), ulceration,
and lymph node involvement.

• Stage 0 (in situ): Confined to the top layer of skin.
• Stage I: Invasive (it has entered deeper layers) but still localized and low risk.
• Stage II: Still localized, but thicker and/or ulcerated, so higher risk of coming back.
• Stage III: Spread to nearby lymph nodes or nearby skin (regional spread).
• Stage IV: Spread to distant organs or distant lymph nodes (metastatic melanoma).

One more concept matters a lot: resectable vs. unresectable. Resectable means it can be removed with surgery.
Unresectable means surgery isn’t likely to remove it all safely, so systemic treatment (therapy that travels through your body)
usually leads.

Stage 0 Melanoma (Melanoma In Situ): “Remove It With a Safety Buffer”

Typical treatment

Stage 0 melanoma is usually treated with wide excision surgeryremoving the melanoma plus a margin of normal-looking
skin around it. Think of it like removing a spill on a rug: you don’t just blot the wet spot; you clean a little beyond it so
it doesn’t linger.

For melanoma in situ, margins are often in the 0.5 to 1.0 cm range (the exact margin depends on location and clinical factors).
After removal, the tissue is examined under a microscope. If melanoma cells are found at the edges (“positive margins”), you may need a second
procedure to clear the remaining cells.

Special situations

Some in situ melanomasespecially on the facecan be harder to clear with standard excision without creating a big functional or cosmetic tradeoff.
In selected cases, specialists may use staged approaches (where tissue is removed and checked in steps) to balance complete removal with tissue-sparing.
The details depend on the lesion type and the expertise available.

What usually comes next

Stage 0 typically doesn’t require immunotherapy, chemotherapy, or radiation. Follow-up focuses on skin checks (because people who’ve had one melanoma
are at higher risk for another).

Stage I Melanoma: Surgery First, With a Sentinel Node “GPS Check” for Some

Typical treatment

Stage I melanoma is usually treated with wide local excision. The margin size depends mainly on tumor thickness and location. For thinner melanomas,
the margin is smaller; for thicker ones, the margin increases (while still keeping function and anatomy in mind).

Sentinel lymph node biopsy (SLNB): when it’s discussed

For some stage I melanomasespecially those around or above 0.8 mm thickness and/or with ulcerationdoctors may recommend discussing a
sentinel lymph node biopsy. The sentinel node is the first lymph node (or nodes) that drains from the tumor area. If melanoma is going to travel,
it often shows up there first.

SLNB is most helpful for staging and risk assessment. A negative sentinel node is reassuring. A positive sentinel node can shift the stage and influence whether
adjuvant (after-surgery) therapy is recommended.

Adjuvant therapy at stage I?

Most stage I melanomas do not require adjuvant systemic therapy. Many people move into surveillance: regular skin exams, physical exams, and education
on sun protection and self-skin checks.

Stage II Melanoma: Still Localized, But Higher-RiskSo the “After Surgery” Conversation Gets Real

Typical treatment

Stage II melanoma is still treated primarily with wide excision. Because stage II tumors are thicker and/or ulcerated, doctors often strongly consider
a sentinel lymph node biopsy to check for microscopic spread.

Some patients may also get imaging depending on symptoms, exam findings, or the exact risk profileespecially as stage II risk increases (for example, stage IIB/IIC).
Not everyone needs scans right away, but your team may use them strategically.

Adjuvant immunotherapy for high-risk stage II (IIB/IIC)

Here’s where melanoma treatment has changed a lot in recent years. For high-risk stage II (especially stage IIB and IIC) after complete surgical resection,
doctors may recommend adjuvant immunotherapymost commonly anti–PD-1 checkpoint inhibitors (such as pembrolizumab or nivolumab).

The goal is to lower the chance the melanoma comes back somewhere else later. It’s not a guarantee, and it’s not “free of strings” (immune-related side effects are
a real consideration), but it’s now part of standard discussions for many stage IIB/IIC patients.

When radiation is considered in stage II

Radiation therapy is not routine for most stage II primary tumors. It may be considered in special situationssuch as when surgical margins can’t be cleared or if there
are unusual high-risk featuresdepending on the care team and tumor location.

Stage III Melanoma: Regional Spread Means a Team Sport (Surgery + Systemic Therapy)

Typical treatment: remove what’s removable

Stage III melanoma means melanoma has reached nearby lymph nodes and/or nearby skin areas (satellite or in-transit metastases). If the disease is resectable, treatment
often starts with surgery:

• Wide excision of the primary site (if not already done).
• Management of involved lymph nodes (this might include removing clinically involved nodes).
• Management of in-transit/satellite lesions if present and operable.

If a sentinel node is positive, many centers now favor careful ultrasound surveillance of the nodal basin rather than automatically doing a full “completion” lymph node dissection,
depending on clinical specifics. The modern approach often aims to reduce surgical complications (like lymphedema) without sacrificing outcomes.

Adjuvant therapy: lowering recurrence risk after surgery

For resected stage III melanoma, adjuvant systemic therapy is commonly recommended because recurrence risk is higher:

• Adjuvant immunotherapy: anti–PD-1 checkpoint inhibitors (like pembrolizumab or nivolumab) are common choices.
• Adjuvant targeted therapy (if BRAF V600 mutation-positive): BRAF/MEK inhibitor combinations (such as dabrafenib + trametinib) may be an option.
  This is why tumor testing matters.

The choice depends on mutation status, side effect profiles, other medical conditions, and shared decision-making (aka: you get a vote).

Neoadjuvant therapy: treating before surgery (in selected cases)

Neoadjuvant immunotherapytreatment before surgeryis increasingly discussed for certain high-risk stage III presentations (particularly bulky node-positive disease),
often guided by emerging clinical trial data and specialist experience. This approach aims to shrink disease, treat microscopic spread early, and potentially improve outcomes.
Availability varies, and it’s often offered in specialized centers and/or clinical trials.

Radiation therapy in stage III

Radiation might be used after surgery in select situations, such as higher-risk nodal disease or when local control is a concern. It can also be used for symptom relief if melanoma
is causing pain or compressing structures.

Stage IV Melanoma: Metastatic Disease Usually Means Systemic Therapy Leads

Stage IV melanoma means the cancer has spread beyond the regional areaoften to organs like the lungs, liver, brain, bone, or distant lymph nodes/skin.
Treatment here is usually about controlling disease throughout the body, improving survival, and maintaining quality of life. And yesmany people do remarkably well with modern therapy.

First-line systemic therapy: immunotherapy and targeted therapy

For many patients, immunotherapy is the backbone of stage IV treatment. Common approaches include:

• Anti–PD-1 therapy (e.g., pembrolizumab or nivolumab).
• Combination immunotherapy (e.g., nivolumab + ipilimumab) for selected patients who can tolerate more immune-related side effects.
• Nivolumab + relatlimab (a fixed-dose combination that targets PD-1 and LAG-3) for unresectable or metastatic melanoma in appropriate patients.

If the tumor has a BRAF V600 mutation, targeted therapy with a BRAF inhibitor plus a MEK inhibitor can be highly effective and often works quickly.
It’s especially useful when rapid tumor shrinkage is needed. The tradeoff is that targeted therapy can lose effectiveness over time in some cases, while immunotherapy can produce
durable long-term responses for a subset of patients.

Local treatments still matter

Even in stage IV, local treatments can play a role:

• Surgery may remove isolated metastases in carefully selected patients.
• Radiation therapy can control symptoms or treat specific sites (brain metastases are often treated with focused radiation techniques when appropriate).
• Intralesional therapy (injecting medication into tumors) may be used in certain scenarios, particularly for accessible skin or lymph node lesions.

Later-line options: TIL therapy and clinical trials

If melanoma progresses after standard immunotherapy (and targeted therapy when relevant), other options can be considered. One newer approach is
tumor-infiltrating lymphocyte (TIL) therapy, which uses a patient’s own tumor-fighting immune cells collected from a tumor sample, expanded in a lab, and then reinfused.
In the U.S., lifileucel (Amtagvi) received accelerated FDA approval for certain previously treated metastatic melanoma patients.

Clinical trials remain a major part of stage IV carebecause melanoma research moves fast, and trials may offer access to promising combinations and next-generation therapies.

Palliative care: not a “last resort,” but a quality-of-life upgrade

Palliative care focuses on symptoms, stress, sleep, appetite, pain control, and emotional supportat any stage, including while receiving active treatment. It’s a “support team,” not a surrender flag.

Recurrent Melanoma: Treatment Depends on Where It Came Back

Melanoma can recur locally (near the original site), regionally (nearby nodes/skin), or distantly (metastatic recurrence). Treatment is based on the pattern:

• Local recurrence: often treated with surgery when feasible, sometimes with added systemic therapy depending on risk.
• Regional recurrence: may involve surgery and/or systemic therapy and sometimes radiation.
• Distant recurrence: treated like stage IV disease with systemic therapy leading, plus local control where helpful.

If you’ve had melanoma before, follow-up visits are partly about catching recurrence earlyand partly about catching any new melanoma early. Your future self will thank you for those appointments.

Common Questions to Ask Your Care Team (Bring This List)

• What stage is my melanoma, and what features make it higher or lower risk?
• What surgical margin is recommended for my tumor thickness and location?
• Do you recommend a sentinel lymph node biopsy? Why or why not?
• Should my tumor be tested for mutations (like BRAF), and how would results change treatment?
• Am I a candidate for adjuvant immunotherapy or targeted therapy after surgery?
• What side effects should I watch for with immunotherapy (and when should I call you)?
• What follow-up schedule do you recommend for skin exams, imaging, and lab work?
• Are clinical trials a good fit for my stage and risk profile?

What Treatment Feels Like: Real-World Experiences (About )

Facts and treatment charts are helpful, but melanoma is also a human experienceone with waiting rooms, “we got the pathology back” phone calls, and a sudden increase in how often you
stare at your own skin like you’re inspecting a used car in daylight.

Stage 0 experiences are often described as “surprisingly simple, emotionally loud.” Many people say the procedure itself (wide excision) felt manageablelocal anesthesia,
some tugging, stitches, then healing. The bigger impact is psychological: “I came in for a weird freckle and left with the word cancer.” A common next step is becoming the most sunscreen-loyal
person in your neighborhood. People often talk about learning scar care, watching for infection, and realizing follow-up skin checks are now a permanent subscription (no free trial, sorry).

Stage I experiences can feel like stage 0 with extra homework. If a sentinel lymph node biopsy is recommended, patients often describe it as the “GPS check”:
a dye or tracer maps where the melanoma would drain, then the surgeon removes a small number of sentinel nodes. Many people report the recovery was still very doable, but they remember the
anxiety of waiting for node results more than they remember the incision. A negative sentinel node can bring a wave of relief; a positive result can turn the calendar into a blur of consults.

Stage II experiences vary widely because stage II ranges from moderate to high risk. People with stage IIB/IIC often describe a big decision point after surgery:
“Do I do adjuvant immunotherapy?” Some choose it for peace of mind and recurrence risk reduction; others weigh side effects and decide on close surveillance. Those who take anti–PD-1 therapy
commonly describe the routine as “infusion, labs, repeat,” with fatigue and skin symptoms being frequent annoyances. A key real-world theme: learning which side effects are “normal tired” versus
“call the clinic today,” since immunotherapy can sometimes trigger inflammatory issues that need quick attention.

Stage III experiences are often described as “team sport medicine.” Patients talk about meeting a dermatologist, surgeon, medical oncologist, and sometimes radiation oncologyplus imaging,
mutation testing, and treatment sequencing. Adjuvant therapy can feel like a marathon: not always dramatic day-to-day, but psychologically heavy because it represents the risk of recurrence. Some people
describe relief at having a plan; others describe the challenge of living in “scanxiety season.”

Stage IV experiences tend to center on systemic therapy and uncertaintymixed with genuine hope. Many patients describe immunotherapy as strange in the best and worst ways: it may not cause
immediate “I feel poisoned” chemotherapy vibes, but it can cause unpredictable immune side effects. People often mention learning to advocate for themselves early, keeping a symptom log, and bringing a friend
to big appointments for note-taking. Some talk about targeted therapy working quickly (especially when tumors are BRAF-mutant), sometimes with side effects like fever, rash, or joint aches. And many emphasize
how much supportive care matterssleep, nutrition, movement when possible, mental health support, and practical planningbecause treatment is not only about fighting cancer; it’s also about living while you do it.

If there’s one shared thread across stages, it’s this: melanoma treatment is increasingly personalized. People often feel better once they understand why their plan fits their stage, their risk factors,
and their tumor biology. Clarity doesn’t erase fearbut it does make the next step feel doable.

Conclusion

How melanoma is treated at each stage comes down to a simple principle with lots of nuance: remove what can be removed, then reduce recurrence risk (or control spread) with the smartest therapy for the job.
Early stages lean heavily on surgery. Higher-risk stage II adds meaningful “after surgery” decisions, including adjuvant immunotherapy for many patients. Stage III is usually a combination approach: surgery plus
systemic therapy, sometimes with radiation. Stage IV relies on systemic therapyespecially immunotherapy and targeted therapywith local treatments used strategically.

If you’re facing melanoma, ask your team to explain your stage, your tumor features, and your options in plain language. A good plan should feel evidence-based, personalized, and understandablebecause you
shouldn’t need a medical dictionary to feel confident about your own care.